CAJ | 학술논문

目的：比较替吉奥单药与替吉奥联合多西他赛治疗老年晚期胃癌的疗效及安全性。方法整群选取2013年1月-2014年12月间该院肿瘤科收治的83例老年晚期胃癌患者随机分为单药组和联合组。单药组予替吉奥化疗，联合组予替吉奥联合多西他赛化疗，一周期均为21 d。化疗4周期后评价疗效及不良反应。结果单药组及联合组的近期疗效比较差异无统计学意义(P>0.05)；单药组不良反应总体上比联合组低，其中恶性呕吐、肝功能异常发生率差异有统计学意义(P<0.05)；临床获益率单药组高，两组差异有统计学意义(P<0.05)。结论替吉奥单药与替吉奥联合多西他赛治疗老年晚期胃癌对比，疗效相当，患者耐受性较好，不良反应减轻减少，生存质量提高。
목적：비교체길오단약여체길오연합다서타새치료노년만기위암적료효급안전성。방법정군선취2013년1월-2014년12월간해원종류과수치적83례노년만기위암환자수궤분위단약조화연합조。단약조여체길오화료，연합조여체길오연합다서타새화료，일주기균위21 d。화료4주기후평개료효급불량반응。결과단약조급연합조적근기료효비교차이무통계학의의(P>0.05)；단약조불량반응총체상비연합조저，기중악성구토、간공능이상발생솔차이유통계학의의(P<0.05)；림상획익솔단약조고，량조차이유통계학의의(P<0.05)。결론체길오단약여체길오연합다서타새치료노년만기위암대비，료효상당，환자내수성교호，불량반응감경감소，생존질량제고。
Objective To evaluate the clinical efficacy and adverse reaction of the S-1 and S-1 combined with docetaxel in the treatment of elderly patients with advanced gastric cancer. Methods Eighty-three elderly patients with advanced gastric cancer were divided into trial group and control group. In the trial group, S-1 was administered orally twice daily from d1 to d14. In the control group, S-1 was administered in the same way, and intravenous of docetaxel was administered in the first day. 21 days for a cycle and continue for 4 cycles. Results For the two groups, there were no significant differences in RR and DCR (P>0.05). But there were significant differences in clinical benefit rate and partial adverse reactions as vomiting and liver function damage (P<0.05). Conclusions The S-1 capsule has shown activity for elderly patients in treatment of advanced gastric cancer, and it is well-tolerated.